PHER O2

Drug Profile

PHER O2

Latest Information Update: 06 Dec 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanguine Corporation
  • Class Fluorocarbons
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Diabetes mellitus; Hypovolaemia

Most Recent Events

  • 06 Dec 2006 Sanguine has met with the US FDA to discuss the appropriate regulatory path for PHER 02
  • 21 Nov 2005 Preclinical trials in Diabetes mellitus in USA (unspecified route)
  • 22 Dec 2004 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top